Magnevist® Injection enhanced MRA compared to non contrast MRA for the detection of structural abnormalities of the aortic arch and cerebral branches
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the aortic arch and cerebral branches. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.
- Has known or suspected disease of the aortic arch and cerebral branches - Is scheduled for X-ray angiography
- Has any contraindication to magnetic resonance imaging - Is scheduled for any procedure before the X-ray angiography - Had previous bilateral intervention (surgery, bypass) of the arteries of interest
Multicenter, open-label study of the safety (open-label) and efficacy (open-label and blinded reader) of a single administration of approximately 0.1 mmol/kg of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in patients with known or suspected disease of the aortic arch and cerebral branches who are undergoing MRA of these vessels with intra-arterial digital subtraction arteriography (i.a. DSA) as the standard of reference.
Single Group Assignment